Search clinical trials for: Talimogene Laherparepvec (T-VEC)

Total 11017 results

University of Zurich

Completed

T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)

Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer | Cutaneous Lymphoma

Switzerland
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Karie D. Runcie, MD
Amgen

Active, not recruiting

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Amgen

Completed

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Melanoma | Merkel Cell Carcinoma | Other Solid Tumors

United States
Dan Blazer III, M.D.

Completed

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)

Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected

United States
University of California, Davis
Amgen

Suspended

Neoadjuvant T-VEC in High Risk Early Melanoma

Melanoma

United States
Royal Marsden NHS Foundation Trust

Completed

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (TITAN)

Melanoma and Sarcoma

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

Angiosarcoma of Skin

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Sarcoma | Epithelioid Sarcoma | Cutaneous Angiosarcoma

United States
Amgen

Completed

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Unresectable Stage IIIB-IV Malignant Melanoma

Japan
BioVex Limited
Symbion Research International

Completed

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Melanoma

United Kingdom, United States
BioVex Limited
Covance

Completed

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Melanoma
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
TriHealth Inc.
TriHealth Cancer Institute; TriHealth Surgical Institute; TriHealth Ultrasound... and other collaborators

Withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Melanoma (Skin) | Tumor Skin | BRAF Gene Mutation | Melanoma Stage IIIb-IVM1a | Metastasis Skin

United States
BioVex Limited

Completed

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
Norwegian University of Science and Technology
Helse Nord-Trøndelag HF

Completed

Psychoeducational Groups for Adults With ADHD

Attention Deficit Hyperactivity Disorder

Norway
University of California, San Francisco
Amgen

Active, not recruiting

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China, Taiwan
Amgen

Completed

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Melanoma

United States, France, Germany
University of Louisville

Recruiting

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Cutaneous Melanoma

United States
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel; ClinChoice Enterprise Management (Shanghai) Limited

Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
BioVex Limited
Amgen

Completed

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Melanoma

United States, United Kingdom, Canada, South Africa
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Vecmedical Spain, S.L.

Recruiting

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device (UNI-VEC)

Rectal Polyp | Rectal Lesion | Sessile Colonic Polyp | Rectal Polyps | Pedunculated Colorectal Polyps

Spain
Chengdu Kanghong Biotech Co., Ltd.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Recruiting

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Retinoblastoma

China
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Malignant Chest Wall Neoplasm | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Helse Nord-Trøndelag HF

Recruiting

Cognitive Training for Patients With Eating Disorders (TCRTRCT)

Anorexia Nervosa | Feeding and Eating Disorders | Binge-Eating Disorder | Bulimia Nervosa

Norway
University of California, San Francisco
Amgen

Withdrawn

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Healthy

United States
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Melanoma

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Lynk Biotechnologies Pte Ltd
T&T Family Health Clinic and Surgery, Singapore; Temasek Polytechnic School...

Completed

Transdermal Delivery of Glucosamine to the Synovial Fluid of Male and Female With Knee Osteoarthritis

Osteoarthritis, Knee

Singapore
Biotronik SE & Co. KG

Completed

Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy (REFORM)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Czech Republic

Search clinical trials for: Talimogene Laherparepvec (T-VEC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations